News Releases

Mar. 9, 2001

Sumitomo Seiyaku Biomedical, Co., Ltd. to Launch on April 1

Sumitomo Seiyaku Biomedical, Co., Ltd., operated through joint investment by Sumitomo Pharmaceuticals, Co., Ltd. (Head Office: Osaka City; President: Masaaki Yokotsuka) and Nihon Medi-Physics, Co., Ltd. (Head Office: Nishinomiya City; President: Hidehiko Nakamura), will be in business as of April 1, 2001, having provisionally selected its executive staff. In order to strengthen and expand the business in in-vitro diagnostics, the new company will inherit the past expertise its predecessors have each obtained on its own and continue to pursue research, development, manufacturing, and sales in this field.

In-vitro diagnostics promise great potential, as they are indispensable in preventive medicine, accurate diagnosis of the type and cause of disease, and appropriate selection and application of therapeutics. The company will, for the time being, concentrate on expansion in such fields as bone metabolism and calcium metabolism. Furthermore, it will endeavor to broaden its business activity to other fields, including POC examination, in cooperation with other corporations. *

Making effective use of the resources provided by its mother companies, Sumitomo Seiyaku Biomedical will do its utmost to strengthen its operational base and to satisfy customers with ever-improving products for clinical examinations.

* POC (Point of Care) examination: A simple and quick diagnostic evaluation system used by doctors in clinics and hospitals. There have been several systems already developed and marketed: e.g., for pregnancy test agents and diabetes diagnostic systems.

Corporate Data

Trade name : Sumitomo Seiyaku Biomedical, Co., Ltd.
Executive staff
(as of April 1)
: Atsushi Murano, Ph.D., President
Noriaki Ohmura, Managing Director
Yoshiaki Murakami, Director
Tadayoshi Nishimura, Director
Hiroshi Masuda, Director
Kouji Mizobe, Auditor
Location of the Head office : 2-2-8, Doshomachi, Chuo-ku, Osaka City
Commencement of operation : April 1, 2001
Capital : ¥480 million
Shareholders (investment ratio) : Sumitomo Pharmaceuticals, Co., Ltd. (90%)
Nihon Medi-Physics, Co., Ltd. (10%)
Number of employees : appx. 50
Line of business : The research, development, manufacturing, sales, import and export of diagnostics, reagents, medical equipment and measuring instruments for medical sciences
Business bases :
Head Office 2-1-1, Fushimi-cho, Chuo-ku, Osaka, Japan
Tokyo Branch 3-11, Kanda-Surugadai, Chiyoda-ku, Tokyo, Japan
Hyogo Factory 9-1, Techno-Park, Sanda, Hyogo, Japan